Jeffrey W. Albers Sells 6,349 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Jeffrey W. Albers sold 6,349 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $311,101.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Kymera Therapeutics Stock Performance

KYMR stock opened at $47.66 on Friday. The firm has a market cap of $3.10 billion, a P/E ratio of -20.37 and a beta of 2.07. The firm’s fifty day moving average is $29.81 and its 200 day moving average is $35.74. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.10. The firm had revenue of $22.10 million for the quarter, compared to analysts’ expectations of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company’s revenue for the quarter was up 114.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.69) earnings per share. As a group, analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Blue Trust Inc. increased its stake in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after purchasing an additional 270 shares during the period. KBC Group NV grew its holdings in shares of Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company’s stock worth $68,000 after purchasing an additional 328 shares during the last quarter. Summit Investment Advisors Inc. increased its stake in shares of Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock worth $198,000 after buying an additional 406 shares during the period. Comerica Bank increased its stake in shares of Kymera Therapeutics by 3.6% in the first quarter. Comerica Bank now owns 21,374 shares of the company’s stock worth $585,000 after buying an additional 743 shares during the period. Finally, Hsbc Holdings PLC raised its holdings in Kymera Therapeutics by 6.1% during the 1st quarter. Hsbc Holdings PLC now owns 18,547 shares of the company’s stock valued at $508,000 after buying an additional 1,064 shares during the last quarter.

Analysts Set New Price Targets

KYMR has been the topic of several research analyst reports. Stifel Nicolaus assumed coverage on shares of Kymera Therapeutics in a research report on Tuesday, May 20th. They set a “buy” rating and a $55.00 price objective on the stock. B. Riley raised shares of Kymera Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $38.00 to $60.00 in a research report on Tuesday. Bank of America raised Kymera Therapeutics from a “neutral” rating to a “buy” rating and set a $51.00 price target for the company in a research report on Monday. Citigroup assumed coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 price objective for the company. Finally, Morgan Stanley upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $49.00 to $79.00 in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $59.35.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.